Hikma Pharmaceuticals Plc
12 June 2006
Section 198 Notification
London, 12 June 2006 - On 12 June 2006, Hikma Pharmaceuticals PLC (LSE: HIK)
(DIFX: HIK) ('the Company') received notification from The Capital Group
Companies, Inc., pursuant to Section 198 Companies Act 1985, that at the close
of its business on 31st May 2006, The Capital Group Companies, Inc., on behalf
of its affiliates, including Capital Research and Management Company, had an
interest in 6,183,441 ordinary shares of 10p each in the Company, which
represents 3.696 per cent of the issued ordinary share capital of the Company,
as follows:
No. of shares Percent of ordinary
shares outstanding
The Capital Group
Companies, Inc.
held as follows: 6,183,441 3.696%
Capital Research and
Management Company
of which: 6,183,441 3.696%
SMALLCAP World Fund 5,029,591 3.007%
Registered holders:
State Street Nominees Limited 5,029,591
Chase Nominees Limited 1,153,850
Total 6,183,441
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC +44 20 7399 2670
Henry Knowles, Company Secretary
Susan Ringdal, Investor Relations Director
Brunswick Group LLP +44 20 7404 5959
Jon Coles / Justine McIlroy / Alex Tweed
Notes to Editors
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed pharmaceutical products. Hikma's operations
are conducted through three businesses: Generic, Branded and Injectable
Pharmaceuticals. Hikma's operations are based principally in the United States,
the Middle East and North Africa ('MENA') region and Europe. In 2005, the Group
had revenue of $262 million and profit attributable to shareholders of $44
million. At 31 December 2005, the Group had over 1,800 employees. For news and
other information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.